Biomarin Pharmaceutical (BMRN) Net Cash Flow (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Net Cash Flow came in at $1.8 billion in Q1 2026, up 1538.48% YoY from $107.4 million in Q1 2025, and up 2815.14% on a QoQ basis from $60.4 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Net Cash Flow (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Net Cash Flow data on file, last reported at $1.8 billion in Q1 2026.
- Quarterly Net Cash Flow rose 1538.48% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 billion (up 573.72% YoY) and the FY2025 annual result came in at $371.4 million, up 103.06% from the prior year.
- Net Cash Flow grew to $1.8 billion in Q1 2026, from $60.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.8 billion in Q1 2026 to a low of -$293.8 million in Q3 2024.
- A 5-year average of $145.9 million and a median of $60.4 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow tumbled 947.55% — and 2026, when it surged 1538.48%.
- Tracing BMRN's Net Cash Flow over 5 years: stood at -$37.1 million in 2022, then advanced by 28.11% to -$26.6 million in 2023, then soared by 1094.33% to $264.9 million in 2024, then slumped by 77.22% to $60.4 million in 2025, then surged by 2815.14% to $1.8 billion in 2026.
- The last three Net Cash Flow figures came in at $1.8 billion (Q1 2026), $60.4 million (Q4 2025), and $35.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn | -2.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.20 Bn |
| Jun 30, 2026 | -2.20 Bn |
| Mar 31, 2026 | 1.76 Bn |
| Mar 31, 2026 | 1.76 Bn |
| Dec 31, 2025 | 60.35 Mn |
| Dec 31, 2025 | 60.35 Mn |
| Sep 30, 2025 | 35.55 Mn |
| Sep 30, 2025 | 35.55 Mn |
| Jun 30, 2025 | 168.08 Mn |
| Jun 30, 2025 | 168.08 Mn |
| Mar 31, 2025 | 107.38 Mn |
| Mar 31, 2025 | 107.38 Mn |
| Dec 31, 2024 | 264.89 Mn |
| Dec 31, 2024 | 264.89 Mn |
| Sep 30, 2024 | -293.80 Mn |
| Sep 30, 2024 | -293.80 Mn |
| Jun 30, 2024 | 221.85 Mn |
| Jun 30, 2024 | 221.85 Mn |
| Mar 31, 2024 | -10.06 Mn |
| Mar 31, 2024 | -10.06 Mn |